Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ASCENDIS PHARMA A/S

(ASND)
  Report
Delayed Nasdaq  -  04:00 2022-09-23 pm EDT
100.65 USD   -3.11%
09/22European ADRs Move Lower in Thursday Trading
MT
09/22Wells Fargo Adjusts Ascendis Pharma Price Target to $172 From $167, Maintains Overweight Rating
MT
09/14ASCENDIS PHARMA A/S : Articles of Association - Form 6-K
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Ascendis Pharma A/S : Notice to convene Extraordinary General Meeting - Form 6-K

08/12/2022 | 04:05pm EDT

Notice to convene Extraordinary General Meeting

Notice is hereby given that an extraordinary general meeting of Ascendis Pharma A/S (the "Company") will be held on:

9 September 2022 at 2:00 pm CET

The extraordinary general meeting will be held at:

Mazanti-Andersen Advokatpartnerselskab, Amaliegade 10, DK-1256 Copenhagen K, Denmark

The agenda for the extraordinary general meeting is as follows:

1.

Election of Chairman of the Meeting

2.

Election of new Board Members

3.

Authorisation of the chairman of the meeting

Complete Proposals

Re 1

The Board of Directors proposes that attorney-at-law Lars Lüthjohan is elected as chairman of the general meeting.

Re 2

The Board of Directors proposes that William Carl Fairey Jr and Siham Imani are elected as members of the Board of Directors in Class I, i.e. for a term expiring at the annual general meeting to be held in 2023, so that, if so decided by the shareholders, the board of directors will consists of the following:

Class I, with a term expiring at the annual general meeting to be held in 2023:

Jan Møller Mikkelsen

Lisa Morrison

William Carl Fairey Jr

Siham Imani

Class II, with a term expiring at the annual general meeting to be held in 2024:

Albert Cha

Lars Holtug

Rafaèle Tordjman

William Carl Fairey Jr and Siham Imani have accepted to stand for election in accordance with the above. Information about the current board members and William Carl Fairey Jr and Siham Imani is available on the Company's website www.ascendispharma.com.

Re 3

The board of directors proposes to authorize the chairman of the meeting (with a right of substitution) on behalf of the Company to apply the Danish Business Authority for registration of the resolution passed and in this connection to make any such amendments and supplements to the application and the resolution, including the Company's articles of association and these minutes of the general meeting, that may be required as a condition for registration.

-oo0oo-

The proposals are adopted by a simple majority of the votes cast.

The Company's nominal share capital currently amounts to DKK 56,965,058 consisting of 56,965,058 shares of DKK 1 nominal value. At the general meeting, each share amount of DKK 1 nominal value carries one vote.

Information: The following information is available at the Company's website www.ascendispharma.com as of 12 August 2022.

Notice to convene the extraordinary general meeting

The aggregate number of shares and voting rights as at the date of the notice to convene the general meeting

The documents that will be submitted at the general meeting, including a description of the proposed new member of the Board of Directors.

The agenda and the complete proposals for adoption

Forms for voting by proxy or by mail

The convening notice will also be forwarded in writing to all shareholders recorded in the register of owners who have requested such notification.

A shareholder's right to attend general meetings and to vote at general meetings is determined on the basis of the shares that the shareholder owns on the registration date. The registration date is 2 September 2022. The shares which the individual shareholder owns are calculated on the registration date on the basis of the registration of ownership in the Register of Owners as well as notifications concerning ownership which the company has received with a view to update the ownership in the Register of Owners.

In addition, any shareholder who is entitled to attend a general meeting and who wishes to attend must have requested an admission card from the Company as described below.

Language: The meeting will be conducted in English according to section 7 of the Articles of Association.

Shareholders, proxies and any accompanying adviser must have an admission card to attend the general meeting. Admission cards may be ordered on the Company's website, www.ascendispharma.com or on the website of Computershare A/S, www.computershare.dk.

Admission cards must be ordered no later than 5 September 2022 at 23:59 p.m. (CET).

Proxy: For the general meeting, shareholders may vote by proxy by presenting an instrument of proxy, duly signed and dated. Proxy forms can be downloaded from the website of the Company, www.ascendispharma.com, and must be forwarded to Computershare A/S, Lottenborgsvej 26 D, 1st floor, DK-2800 Kgs. Lyngby, Denmark, by mail or by fax no. + 45 45 46 09 98. Computershare must receive completed proxy forms no later than 8 September 2022 at 12.00 a.m. (CET).

Proxies may also be granted electronically on the Company's website, www.ascendispharma.com, or on the website of Computershare A/S, www.computershare.dk, by using a Computershare username and password. Usernames and passwords will be sent to all shareholders by email. Electronic proxies must be granted no later than 8 September at 12.00 a.m. (CET).

Voting by mail: Shareholders may - instead of voting in person at the ordinary general meeting - choose to vote by mail, i.e. voting in writing prior to the general meeting. Any shareholder who chooses to vote by mail shall send the absentee vote to Computershare A/S, Lottenborgsvej 26 D, 1st floor, DK-2800 Kgs. Lyngby, Denmark, by mail or by fax no. + 45 45 46 09 98.

Electronic voting: It is also possible to vote electronically on the website of Computershare A/S, www.computershare.dk, by using Computershare username and password.

In order to stay valid, the absentee vote must be received by Computershare A/S no later than 8 September 2022 at 12.00 a.m. (CET). Absentee voting forms can also be downloaded from the website of the Company, www.ascendispharma.com. Please note that an absentee vote cannot be withdrawn. Please note that letters may be in the mail for several days.

Hellerup, 12 August 2022

On behalf of the Board of Directors

Albert Cha

Chairman

Disclaimer

Ascendis Pharma A/S published this content on 12 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 August 2022 20:04:06 UTC.


ę Publicnow 2022
All news about ASCENDIS PHARMA A/S
09/22European ADRs Move Lower in Thursday Trading
MT
09/22Wells Fargo Adjusts Ascendis Pharma Price Target to $172 From $167, Maintains Overweigh..
MT
09/14ASCENDIS PHARMA A/S : Articles of Association - Form 6-K
PU
09/13TRANSCRIPT : Ascendis Pharma A/S Presents at Morgan Stanley 20th Annual Global Healthcare ..
CI
09/12Ascendis Pharma A/S Appoints William Carl Fairey Jr. and Siham Imani as Class I Directo..
CI
09/12New Long-Term Data in Adult Patients with Hypoparathyroidism Treated with Ascendis Phar..
AQ
09/12Ascendis Pharma A/S announces new Week 110 data from the Phase 2 PaTH Forward Trial
CI
09/08European ADRs Move Slightly Higher in Thursday Trading
MT
09/07TRANSCRIPT : Ascendis Pharma A/S Presents at Citi's 17th Annual BioPharma Conference, Sep-..
CI
09/01Ascendis Pharma Submits TransCon PTH New Drug Application to the U.S. FDA for Adult Pat..
AQ
More news
Analyst Recommendations on ASCENDIS PHARMA A/S
More recommendations
Financials
Sales 2022 34,8 M 33,8 M 33,8 M
Net income 2022 -501 M -487 M -487 M
Net cash 2022 620 M 603 M 603 M
P/E ratio 2022 -11,5x
Yield 2022 -
Capitalization 5 782 M 5 622 M 5 622 M
EV / Sales 2022 148x
EV / Sales 2023 40,1x
Nbr of Employees 639
Free-Float 10,3%
Chart ASCENDIS PHARMA A/S
Duration : Period :
Ascendis Pharma A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASCENDIS PHARMA A/S
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Last Close Price 103,52 €
Average target price 144,86 €
Spread / Average Target 39,9%
EPS Revisions
Managers and Directors
Jan M°ller Mikkelsen President, CEO & Executive Director
Scott Thomas Smith Chief Financial Officer & Senior Vice President
Albert Cha Chairman
Birgitte Volck SVP, Head-Clinical Development & Medical Affairs
Kennett Sprog°e Senior Vice President, Head-Innovation & Research
Sector and Competitors
1st jan.Capi. (M$)
ASCENDIS PHARMA A/S-25.18%5 622
GILEAD SCIENCES, INC.-13.43%78 787
REGENERON PHARMACEUTICALS, INC.10.42%74 550
VERTEX PHARMACEUTICALS29.08%72 693
BIONTECH SE-50.21%31 192
WUXI APPTEC CO., LTD.-41.46%28 154